Biotech Sector Performance: The biotech sector is experiencing significant stock surges and advancements in trials and regulatory filings, highlighting the importance of distinguishing between short-term price fluctuations and long-term value for investors.
Notable Stock Highlights: Several biotech companies, including Olema Pharmaceuticals, Owlet Inc., and Rigel Pharmaceuticals, have reached new 52-week highs, driven by positive trial results and strategic offerings.
Upcoming Developments: Companies like Jazz Pharmaceuticals and Tarsus Pharmaceuticals are preparing for important regulatory submissions and clinical trials, indicating ongoing innovation and potential market impact.
Financial Outlooks: Firms such as Natera and Kiniksa Pharmaceuticals have provided updated revenue guidance for 2025, reflecting growth expectations and strategic advancements in their respective fields.
Wall Street analysts forecast OLMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OLMA is 42.00 USD with a low forecast of 20.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast OLMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OLMA is 42.00 USD with a low forecast of 20.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 26.100
Low
20.00
Averages
42.00
High
60.00
Current: 26.100
Low
20.00
Averages
42.00
High
60.00
UBS
Buy
initiated
$45
2026-01-07
Reason
UBS
Price Target
$45
AI Analysis
2026-01-07
initiated
Buy
Reason
UBS initiated coverage of Olema Oncology (OLMA) with a Buy rating and $45 price target as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences (IDYA), Inventiva (IVA), SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.
Piper Sandler
Overweight
initiated
$40
2026-01-07
Reason
Piper Sandler
Price Target
$40
2026-01-07
initiated
Overweight
Reason
Piper Sandler initiated coverage of Olema Oncology with an Overweight rating and $40 price target. The firm believes the company's palazestrant can become the next "backbone" endocrine therapy in the large ER+/HER2- breast cancer market.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for OLMA
Unlock Now
Citi
Yigal Nochomovitz
Buy
maintain
$60
2026-01-06
Reason
Citi
Yigal Nochomovitz
Price Target
$60
2026-01-06
maintain
Buy
Reason
Citi analyst Yigal Nochomovitz keeps a Buy rating on Olema Oncology with a $60 price target while adding an "upside 90-day catalyst watch" on the shares. The firm sees opportunities in SMID-cap biotech heading into 2026 for commercial or near-commercial stage companies.
Citi
Buy
maintain
$21 -> $60
2025-12-12
Reason
Citi
Price Target
$21 -> $60
2025-12-12
maintain
Buy
Reason
Citi raised the firm's price target on Olema Oncology (OLMA) to $60 from $21 and keeps a Buy rating on the shares. Citi also added an "upside 90-day catalyst watch" on Olema. The firm says Roche's (RHHBY) positive Phase 3 lidERA trial data shows the "practice changing" potential of selective estrogen receptor degraders for adjuvant treatment of breast cancer. The data bode well for Olema, the analyst tells investors in a research note.
About OLMA
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. It is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
